NCT06675851View on ClinicalTrials.gov

Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline

Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks

DRUG

Cipralex (escitalopram)

Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks

Trial Locations (1)

1090

RECRUITING

Medical University of Vienna, Vienna

All Listed Sponsors
collaborator

Austrian Science Fund (FWF)

OTHER

lead

Medical University of Vienna

OTHER